Psychedelic medicine's moment has arrived – Israel should not sit it out...

For decades psychedelic compounds occupied an uncertain place in medicine, with scientists and patients showing interest while regulators remained cautious. Recent policy shifts include an April 18 executive order signed by President Donald Trump that explicitly includes ibogaine compounds and directs federal agencies to accelerate research.

The article argues that Israel should participate in these developments rather than remain outside the field of psychedelic medicine.